Bayer's Pipeline Math: Two China Approvals, 17 Latin American Launches, and a Cash Flow Still in the Red

Bayer spent this week stacking up reasons for optimism. A fresh Chinese approval for Sevabertinib, a 17-product biologicals plan for Latin America, an upgraded EBITDA outlook and twin target-price hikes from UBS and Goldman Sachs all landed within days of each other. The shares rose 4.5%, though the move was driven by Tuesday's quarterly figures and the raised annual guidance rather than by any single pipeline headline.

The distinction matters, because the two announcements answer different questions. Sevabertinib has been cleared in China for adults with advanced HER2-mutant non-small cell lung cancer, a decision Bayer says rests on data from the ongoing Phase I/II SOHO-01 trial. That is a regulatory outcome, not a revenue line. Asundexian, meanwhile, won Chinese approval on 26 October for reducing stroke risk in adults after non-cardioembolic ischaemic stroke or high-risk TIA. Two green lights in different therapeutic areas give the pharma thesis more breadth than a single asset could — but neither comes with a number attached.

What the guidance actually says

The operating outlook remains the yardstick. On Tuesday Bayer lifted its forecast for currency-adjusted EBITDA before special items to EUR 9.8–10.3 billion for 2026, citing the strength of its pharmaceutical division. That range is a projection, not a result. The third quarter of 2026 delivered EUR 10.053 billion in sales and EUR 1.615 billion in EBITDA before special items — the base from which any improvement has to be built.

Here the two growth stories diverge in timing. The Latin American programme, reported by Reuters, envisages 17 new biological products by 2030, eight of them earmarked for Brazil and spanning biopesticides and plant-performance products. It stretches well beyond the pharma unit Bayer credits as its main growth engine, and it is a multi-year build-out rather than a near-term earnings contributor. Anyone weighing the plan should treat it as a potential additional source of results, not as evidence that the upgraded guidance is locked in.

The balance sheet has not read the press release

The harder counterargument sits in the cash flow statement. Bayer expects free cash flow of minus EUR 1.5 billion to minus EUR 0.5 billion for the current financial year — the improved guidance still foresees an outflow. Net financial debt is projected at EUR 28.0–29.0 billion by year-end. A stronger operating result and extra approvals do not fix that arithmetic on their own; an earnings improvement would carry more weight if it showed up in liquidity too.

Legal risk deserves its own line. On 29 October, all jurors in the first glyphosate trial since the US Supreme Court's ruling sided with Monsanto; according to Bayer, the plaintiffs could not prove their claims. That is a concluded verdict, not a declaration that all glyphosate exposure is closed. Separately, CEO Bill Anderson said on Tuesday he expects a court decision before Christmas in the proposed USD 7.25 billion Roundup settlement, a case pending in a Missouri court at the time of reporting.

Where the bulls and the calendar meet

Analyst sentiment has turned friendlier. UBS raised its target from EUR 62 to EUR 66 and reiterated its buy rating, and Goldman Sachs lifted its own target while keeping a buy recommendation. Both moves point to a more constructive valuation view — neither constitutes a promise of future gains nor proof that the pipeline will pay off commercially.

The next named catalyst is scientific rather than financial: Bayer plans to present new data on cardiovascular disease, kidney conditions and stroke at the American Heart Association's 2026 scientific sessions. Such data can sharpen the medical picture; it cannot substitute for evidence of earnings.

What would settle the argument is confirmation that operations can carry the raised forecast while the announced products move from plan to business. Should that foundation hold, the Latin American build-out and the Chinese approvals broaden the growth story beyond a single division. Should it slip, the market will have to separate long-horizon product ambition from near-term earning power — and price the gap accordingly.